Faron is planning for a Phase III trial, pending U.S Food and Drug Administration (FDA) End of Phase II meeting Feedback TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS ...

Faron is planning for a Phase III trial, pending U.S Food and Drug Administration (FDA) End of Phase II meeting Feedback TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a ...

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the ...

Firm: T & M Financial Inc.